AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21741107 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c≥5.7% and/or FPG≥5.6mmol/l
Number of subjects: 14726
Study 21741107 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c change-points
Number of subjects: 14726
Study 21741107 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG change-points
Number of subjects: 14726
Study 21741107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes incidence
Number of subjects: 14726
Study 20731836 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary primary care intervention
Number of subjects: 360
Study 20731836 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 360
Study 19010047 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) method
Number of subjects: 0
Study 19010047 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom lecture
Number of subjects: 0
Study 16161395 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 120
Study 16161395 — intervention group
Group type: COMPARATOR
Intervention: FC
Number of subjects: 120
Study 12629661 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressants after kidney transplantation
Number of subjects: 3
Study 12629661 — intervention group
Group type: COMPARATOR
Intervention: Extreme training causing immunosuppression
Number of subjects: 3
Study 12629661 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment for hepatitis C virus
Number of subjects: 3
Study 10636496 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 4589
Study 8880059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 0
Study 8880059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1677061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (T)
Number of subjects: 8
Study 1677061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (D)
Number of subjects: 8
Study 6362125 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (single 400 mg oral dose)
Number of subjects: 870
Study 6362125 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (three consecutive days at the same daily dose level)
Number of subjects: 870
Study 6362125 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 870
Study 6362125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 31776344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) adherence intervention
Number of subjects: 566
Study 31776344 — intervention group
Group type: COMPARATOR
Intervention: Advice to quit smoking
Number of subjects: 566
Study 29727302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Clown (HC) present
Number of subjects: 116
Study 29727302 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 116
Study 26285180 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive explosive-type resistance training (RT) twice a week for 10 weeks; four exercises (hip/thigh) performed in three series each (8-12 repetition maximum)
Number of subjects: 80
Study 26285180 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 80
Study 24992750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for 4 weeks
Number of subjects: 240
Study 24992750 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine hydrochloride for 4 weeks
Number of subjects: 240
Study 22622452 — intervention group
Group type: EXPERIMENTAL
Intervention: Online pre-dilution HF (36 patients)
Number of subjects: 146
Study 22622452 — intervention group
Group type: EXPERIMENTAL
Intervention: Online pre-dilution HDF (40 patients)
Number of subjects: 146
Study 22622452 — intervention group
Group type: COMPARATOR
Intervention: Low-flux HD (70 patients)
Number of subjects: 146
Study 20649061 — intervention group
Group type: EXPERIMENTAL
Intervention: ULTRACET
Number of subjects: 180
Study 20649061 — intervention group
Group type: COMPARATOR
Intervention: tramadol and acetaminophen
Number of subjects: 180
Study 18515581 — intervention group
Group type: EXPERIMENTAL
Intervention: off-flap epi-LASIK
Number of subjects: 31
Study 18515581 — intervention group
Group type: COMPARATOR
Intervention: on-flap epi-LASIK
Number of subjects: 31
Study 16579401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaj Yoga combined with conventional anti-depressants
Number of subjects: 30
Study 16579401 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-depressants only
Number of subjects: 30
Study 12028823 — intervention group
Group type: EXPERIMENTAL
Intervention: AD7C‐NTP competitive ELISA test in urine samples from patients with AD
Number of subjects: 3
Study 12028823 — intervention group
Group type: EXPERIMENTAL
Intervention: AD7C‐NTP competitive ELISA test in urine samples from early-AD cases
Number of subjects: 3
Study 12028823 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AD cases
Number of subjects: 3
Study 12028823 — intervention group
Group type: COMPARATOR
Intervention: Overall controls
Number of subjects: 3
Study 10779814 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg oral granisetron solution
Number of subjects: 294
Study 10779814 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/kg oral granisetron solution
Number of subjects: 294
Study 10779814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of granisetron (20 microg/kg and 40 microg/kg)
Number of subjects: 294
Study 8773915 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (primed continuous infusion from t = 1 h to t = 5 h)
Number of subjects: 21
Study 8773915 — intervention group
Group type: COMPARATOR
Intervention: No amino acid infusion (control group)
Number of subjects: 21
Study 8773915 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 21
Study 1475222 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial area method for evaluation of equivalency in the rate of absorption of immediate release formulations.
Number of subjects: 0
Study 1475222 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence interval approach for bioequivalence determinations applied to relevant absorption parameters.
Number of subjects: 0
Study 1475222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff time or point for partial AUC calculation.
Number of subjects: 0
Study 6560420 — intervention group
Group type: EXPERIMENTAL
Intervention: videotaped modeling
Number of subjects: 60
Study 6560420 — intervention group
Group type: EXPERIMENTAL
Intervention: videotaped information
Number of subjects: 60
Study 6560420 — intervention group
Group type: EXPERIMENTAL
Intervention: videotaped information and modeling combined
Number of subjects: 60
Study 6560420 — intervention group
Group type: COMPARATOR
Intervention: control (irrelevant) videotape
Number of subjects: 60
Study 29785102 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching self-management program
Number of subjects: 20
Study 27283622 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaboticaba peel consumption
Number of subjects: 0
Study 27283622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23656430 — intervention group
Group type: EXPERIMENTAL
Intervention: Discourse recounts
Number of subjects: 80
Study 23656430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures for older adults
Number of subjects: 80
Study 23656430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures for younger adults
Number of subjects: 80
Study 22658265 — intervention group
Group type: EXPERIMENTAL
Intervention: Two titanium miniplates with Erich's arch bar for 6 weeks
Number of subjects: 3
Study 22658265 — intervention group
Group type: EXPERIMENTAL
Intervention: Two titanium miniplates without Erich's arch bar
Number of subjects: 3
Study 22658265 — intervention group
Group type: COMPARATOR
Intervention: One titanium miniplate with Erich's arch bar for 6 weeks
Number of subjects: 3
Study 20167702 — intervention group
Group type: EXPERIMENTAL
Intervention: Avosentan 25 mg/d
Number of subjects: 1392
Study 20167702 — intervention group
Group type: EXPERIMENTAL
Intervention: Avosentan 50 mg/d
Number of subjects: 1392
Study 20167702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study 20167702 — intervention group
Group type: EXPERIMENTAL
Intervention: Avosentan
Number of subjects: 1392
Study 18822975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electrogymnastics (AE)
Number of subjects: 153
Study 18822975 — intervention group
Group type: COMPARATOR
Intervention: Traditional electroacupuncture (TEA)
Number of subjects: 153
Study 15956269 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day combined with sertraline 100 mg/day and psychosocial support
Number of subjects: 74
Study 15956269 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with sertraline 100 mg/day and psychosocial support
Number of subjects: 74
Study 11931398 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly 600 mg rifapentine + 15 mg/kg isoniazid (HRp1)
Number of subjects: 672
Study 11931398 — intervention group
Group type: EXPERIMENTAL
Intervention: HRp1 given in 2 of every 3 weeks (HRp1.2/3)
Number of subjects: 672
Study 11931398 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly isoniazid + rifampicin (HR3)
Number of subjects: 672
Study 11984133 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and antioxidants intervention
Number of subjects: 116
Study 11984133 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched, free of polyps)
Number of subjects: 116
Study 9815520 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg orally per day for 2 years
Number of subjects: 1400
Study 9815520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1400
Study 7655833 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE regimen (cisplatin: 20 mg/m2 x day x 5, ifosfamide: 1.8 g/m2 x day x 5, mesna: 1.2 g/m2 x day x 5, etoposide: 100 mg/m2 x day x 5)
Number of subjects: 74
Study 7655833 — intervention group
Group type: COMPARATOR
Intervention: CE regimen (cisplatin: 20 mg/m2 x day x 5, etoposide: 100 mg/m2 x day x 5)
Number of subjects: 74
Study 2462343 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide administered twice daily (group A)
Number of subjects: 101
Study 2462343 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide administered three times daily (group B)
Number of subjects: 101
Study 402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation to the peripheral lymphatics and/or chest wall
Number of subjects: 0
Study 402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus simple mastectomy
Number of subjects: 0
Study 402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation to the peripheral lymphatics and/or chest wall
Number of subjects: 0
Study 402203 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of local recurrence
Number of subjects: 0
Study 6813017 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 6
Study 6813017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31412879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Lactobacillus casei Shirota (LcS) daily for 3 months
Number of subjects: 264
Study 31412879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 29481979 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 sessions of spinal manipulative therapy (SMT)
Number of subjects: 256
Study 29481979 — intervention group
Group type: COMPARATOR
Intervention: 0, 6, 12, or 18 sessions of spinal manipulative therapy (SMT)
Number of subjects: 256
Study 26843373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the supplementary motor area
Number of subjects: 50
Study 26843373 — intervention group
Group type: COMPARATOR
Intervention: TAU (treated as usual with antipsychotics)
Number of subjects: 50
Study 24588789 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 0
Study 24588789 — intervention group
Group type: COMPARATOR
Intervention: No glyceryl trinitrate
Number of subjects: 0
Study 22628591 — intervention group
Group type: EXPERIMENTAL
Intervention: Short anatomical cementless stem
Number of subjects: 70
Study 22628591 — intervention group
Group type: COMPARATOR
Intervention: Conventional cementless stem
Number of subjects: 70
Study 20156981 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 8
Study 20156981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18754763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS)
Number of subjects: 0
Study 18754763 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 16000606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy (300-400 mg/m2) for 3-4 cycles
Number of subjects: 1867
Study 16000606 — intervention group
Group type: COMPARATOR
Intervention: Control (no chemotherapy)
Number of subjects: 1867
Study 16000606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 1867
Study 12873248 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day dexamphetamine (n = 16)
Number of subjects: 30
Study 12873248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study 10232112 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS sutured group
Number of subjects: 0
Study 10232112 — intervention group
Group type: COMPARATOR
Intervention: Medical staff sutured group
Number of subjects: 0
Study 8730431 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 19
Study 8730431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2065826 — intervention group
Group type: COMPARATOR
Intervention: Antituberculous drugs only
Number of subjects: 81
Study 2065826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyaluronidase
Number of subjects: 81
Study 2065826 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide and furosemide in addition to antituberculous treatment
Number of subjects: 81
Study 6406460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (12.5 mg to 100 mg)
Number of subjects: 10
Study 6406460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31593253 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care support and long-term self-management
Number of subjects: 0
Study 29456043 — intervention group
Group type: COMPARATOR
Intervention: Colistin monotherapy (9-million unit loading dose, followed by 4·5 million units twice per day)
Number of subjects: 406
Study 29456043 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (2-g prolonged infusion three times per day)
Number of subjects: 406
Study 29456043 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem
Number of subjects: 406
Study 29456043 — intervention group
Group type: COMPARATOR
Intervention: Colistin monotherapy
Number of subjects: 406
Study 27068631 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg 12 hours before and 400 mg 2 hours before coronary angiography)
Number of subjects: 300
Study 27068631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline infusion)
Number of subjects: 300
Study 27068631 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 300
Study 27068631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24560970 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 70
Study 24560970 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (SWL)
Number of subjects: 70
Study 22794217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/mL berberine
Number of subjects: 0
Study 22794217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/mL berberine plus 1% CHX
Number of subjects: 0
Study 22794217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 0
Study 22794217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 0
Study 22794217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CHX
Number of subjects: 0
Study 22794217 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 0
Study 19274607 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped patient consultation with actors portraying patients with depression symptoms.
Number of subjects: 128
Study 17916078 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 70
Study 17916078 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex- and age-matched subjects)
Number of subjects: 70
Study 16271688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 94
Study 16271688 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric strengthening with stretching
Number of subjects: 94
Study 16271688 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strengthening with stretching
Number of subjects: 94
Study 11902153 — intervention group
Group type: EXPERIMENTAL
Intervention: Studying associates
Number of subjects: 0
Study 11902153 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting prototypes in predictive or incongruous contexts
Number of subjects: 0
Study 10322043 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral median nerve stimulation with brief current pulses at 2 Hz for 800-1,500 trials; 15% of pulses omitted at random intervals.
Number of subjects: 0
Study 9086318 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (5 days/week for 15 weeks, including weight training 2 days/week and aerobic training 3 days/week)
Number of subjects: 17
Study 9086318 — intervention group
Group type: COMPARATOR
Intervention: Control group (team sports program)
Number of subjects: 17
Study 2020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1.0 mg
Number of subjects: 52
Study 2020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 mg
Number of subjects: 52
Study 2020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 3.0 mg
Number of subjects: 52
Study 2020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 mg and 3.0 mg
Number of subjects: 52
Study 2020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 and 3.0 mg
Number of subjects: 52
Study 2020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (all doses)
Number of subjects: 52
Study 7195004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose elimination diet
Number of subjects: 103
Study 7195004 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 103
Study 7195004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose malabsorbers
Number of subjects: 103
Study 7195004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose absorbers
Number of subjects: 103
Study 7195004 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 103
Study 7195004 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent abdominal pain group
Number of subjects: 103
Study 31306506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% magnesium sulphate added to 1.8% lidocaine with 1:88,000 epinephrine
Number of subjects: 68
Study 31306506 — intervention group
Group type: COMPARATOR
Intervention: 1.8% lidocaine with 1:88,000 epinephrine
Number of subjects: 68
Study 29680319 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 sessions of cognitive and/or behavioral intervention tailored to symptom severity across 12 months along with routine medical care
Number of subjects: 139
Study 29680319 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 139
Study 26387689 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting
Number of subjects: 8
Study 26387689 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 8
Study 26387689 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 8
Study 22855822 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding brain scores reflecting hippocampal functioning
Number of subjects: 292
Study 22855822 — intervention group
Group type: EXPERIMENTAL
Intervention: General cognitive-control network scores
Number of subjects: 292
Study 22855822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hippocampus activity
Number of subjects: 292
Study 22855822 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain structure analyses
Number of subjects: 292
Study 20520283 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID
Number of subjects: 458
Study 20520283 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg BID
Number of subjects: 458
Study 20520283 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 4 mg BID
Number of subjects: 458
Study 20520283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 18516753 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current therapy
Number of subjects: 40
Study 18516753 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback pelvic floor exercises
Number of subjects: 40
Study 15960566 — intervention group
Group type: COMPARATOR
Intervention: No SUD
Number of subjects: 1000
Study 15960566 — intervention group
Group type: EXPERIMENTAL
Intervention: Current SUD
Number of subjects: 1000
Study 15960566 — intervention group
Group type: EXPERIMENTAL
Intervention: Past SUD
Number of subjects: 1000
Study 12424330 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato sauce supplementation (30 mg of lycopene/day) for 3 weeks
Number of subjects: 32
Study 10622345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU), 20 mg QD for 11 weeks
Number of subjects: 20
Study 10622345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20